Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016:12:27.
doi: 10.1007/s11306-015-0930-4. Epub 2016 Jan 6.

Metabolomic biomarkers for personalised glucose lowering drugs treatment in type 2 diabetes

Affiliations

Metabolomic biomarkers for personalised glucose lowering drugs treatment in type 2 diabetes

Henk den Ouden et al. Metabolomics. 2016.

Abstract

We aimed to identify metabolites to predict patients' response to glucose lowering treatment during the first 5 years after detection of type 2 diabetes. Metabolites were measured by GC-MS in baseline samples from 346 screen-detected type 2 diabetes patients in the ADDITION-NL study. The response to treatment with metformin and/or sulphonylurea (SU) was analysed to identify metabolites predictive of 5 year HbA1c change by multiple regression analysis. Baseline glucose and 1,5 anhydro-glucitol were associated with HbA1c decrease in all medication groups. In patients on SU no other metabolite was associated with HbA1c decrease. A larger set of metabolites was associated with HbA1c change in the metformin and the combination therapy (metformin + SU) groups. These metabolites included metabolites related to liver metabolism, such as 2-hydroxybutanoic acid, 3-hydroxybutanoic acid, 2-hydroxypiperidine and 4-oxoproline). Metabolites involved in oxidative stress and insulin resistance were higher when the HbA1c decrease was larger in the metformin/sulphonylurea group. The associations between baseline metabolites and responsiveness to medication are in line with its mode of action. If these results could be replicated in other populations, the most promising predictive candidates might be tested to assess whether they could enhance personalised treatment.

Keywords: Metabolomics; Metformin; Personalised medicine; Sulphonylurea.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Relative HbA1c after 5 years for each medication group (∆ %HbA1c = ((t5-t0/t0)*100 %)) (C = no medication, M = metformin, M + S = combination metformin and sulphonylurea, S = sulphonylurea, red mean, pink 1 SD, blue 95 % confidence interval and ash individual data), n = 264 (Color figure online)

References

    1. Aquilante CL. Sulfonylurea pharmacogenomics in Type 2 diabetes: the influence of drug target and diabetes risk polymorphisms. Expert Review of Cardiovascular Therapy. 2010;3:359–372. doi: 10.1586/erc.09.154. - DOI - PMC - PubMed
    1. Bain JR, Stevens RD, Wenner BR, et al. Metabolomics applied to diabetes research: Moving from information to knowledge. Diabetes. 2009;58:2429–2443. doi: 10.2337/db09-0580. - DOI - PMC - PubMed
    1. Bao Y, Zhao T, Wang X, et al. Metabonomic variations in the drug-treated type 2 diabetes mellitus patients and healthy volunteers. Journal of Proteome Research. 2009;8:1623–1630. doi: 10.1021/pr800643w. - DOI - PubMed
    1. Benjamini Y, Hochberg Y. Controlling the false discovery rate: A practical and powerful approach to multiple testing. Journal of the Royal Statistical Society: Series B (Methodological) 1995;57:289–300.
    1. Bertolo RF, Burrin DG. Comparative aspects of tissue glutamine and proline metabolism. Journal of Nutrition. 2008;138:2032–2039. - PubMed

LinkOut - more resources